- In August 2020, Greiner Bio-One and Haematologic Technologies announced a strategic collaboration to offer comprehensive end-to-end development and custom manufacturing services for blood collection tubes tailored to the needs of IVD and clinical diagnostic device developers. This collaboration enhances innovation and customization in blood collection tube manufacturing, addressing the growing demand for precision diagnostics. As the market shifts toward more specialized and high-performance diagnostic solutions, such strategic alliances play a crucial role in advancing product quality and accelerating time to market, ultimately supporting the global expansion and technological advancement of venous blood collection devices
- In July 2020, Magnolia Medical introduced the Steripath Gen2 Initial Specimen Diversion Device, featuring an integrated syringe designed to enhance precision in blood sample collection, particularly for patients with compromised vasculature. The launch of the Steripath Gen2 reflects the market’s ongoing shift toward more accurate, patient-centric blood collection solutions. As the demand for diagnostic reliability grows, especially among vulnerable patient populations, technologically advanced devices like this contribute to improved clinical outcomes and reinforce the importance of innovation in driving market growth globally
- In March 2022, Vivasure Medical announced that the first patient had been enrolled in a U.S. early feasibility study evaluating its next-generation PerQseal+ device. PerQseal+ is designed for use in percutaneous transcatheter aortic valve replacement (TAVR) procedures and represents a significant advancement in vascular closure technology. These advancements complement the broader ecosystem of venous access and blood collection, emphasizing safety, ease of use, and improved patient outcomes, factors that are also propelling growth in the venous blood collection devices market
- In February 2022, Roche's Foundation Medicine received regulatory approval for an assay designed to detect circulatory tumor DNA (ctDNA) in plasma. This assay, which has been granted FDA breakthrough designation, is intended for the detection of molecular residual disease (MRD) in cancer patients following curative therapy. The approval of ctDNA assays underscores the growing importance of non-invasive blood-based diagnostic technologies in personalized medicine. This trend aligns with the increasing demand for advanced blood collection devices, as accurate sample collection and handling are essential for ensuring reliable diagnostic results
- In February 2024, Tasso, Inc. introduced Tasso Care for Prescreening, a comprehensive end-to-end service solution designed to improve the efficiency of prescreening programs. The launch of Tasso Care for Prescreening highlights the growing demand for innovative blood collection solutions in clinical trials. By integrating remote blood collection capabilities, Tasso is contributing to the shift toward more accessible and efficient healthcare services, which increases the need for advanced venous blood collection devices
